These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30017176)

  • 21. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The polypill: optimal strategy for reduction of cardiovascular disease].
    Nathoe HM; Doevendans PA
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Polypill in the prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
    [No Abstract]   [Full Text] [Related]  

  • 24. Combined use of polypill components in patients with type 2 diabetes mellitus.
    Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M;
    Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The polypill: not an effective strategy for reduction of cardiovascular disease].
    Westerweel PE; van Wijk JP; Verhaar MC
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial.
    Mariani J; Rosende A; De Abreu M; Gonzalez Villa Monte G; D'Imperio H; Antonietti L; Lemonnier G; de Bonis A; Tajer C
    Ther Adv Cardiovasc Dis; 2020; 14():1753944720912071. PubMed ID: 32186246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cardiovascular polypill in high-risk patients.
    Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
    Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy to prevent cardiovascular disease: slow progress.
    Smith R; McCready T; Yusuf S
    JAMA; 2013 Apr; 309(15):1595-6. PubMed ID: 23529576
    [No Abstract]   [Full Text] [Related]  

  • 30. Effectiveness of polypill for primary and secondary prevention of cardiovascular disease: a pragmatic cluster-randomised controlled trial (PolyPars).
    Malekzadeh F; Gandomkar A; Poustchi H; Etemadi A; Roshandel G; Attar A; Abtahi F; Sadeghi Boogar S; Mohammadkarimi V; Fattahi MR; Mohagheghi A; Malekzadeh R; Sepanlou SG
    Heart; 2024 Jun; 110(14):940-946. PubMed ID: 38485210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg.
    González-Juanatey JR
    Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):595-596. PubMed ID: 29752030
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
    Yusuf S; Pais P; Sigamani A; Xavier D; Afzal R; Gao P; Teo KK
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):463-71. PubMed ID: 22787067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
    Xavier D; Pais P; Sigamani A; Pogue J; Afzal R; Yusuf S;
    Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):96-7. PubMed ID: 19104516
    [No Abstract]   [Full Text] [Related]  

  • 34. The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease.
    Hedner T; Kjeldsen SE; Narkiewicz K; Oparil S
    Blood Press; 2016 Oct; 25(5):276-9. PubMed ID: 27071504
    [No Abstract]   [Full Text] [Related]  

  • 35. PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol.
    Merat S; Poustchi H; Hemming K; Jafari E; Radmard AR; Nateghi A; Shiravi Khuzani A; Khoshnia M; Marshall T; Malekzadeh R
    Arch Iran Med; 2015 Aug; 18(8):515-23. PubMed ID: 26265520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of Polypill for Prevention of Cardiovascular Disease (PolyPars): Protocol of a Randomized Controlled Trial.
    Malekzadeh F; Gandomkar A; Malekzadeh Z; Poustchi H; Moghadami M; Fattahi MR; Moini M; Anushiravani A; Mortazavi R; Sadeghi Boogar S; Mohammadkarimi V; Abtahi F; Merat S; Sepanlou SG; Malekzadeh R
    Arch Iran Med; 2020 Aug; 23(8):548-556. PubMed ID: 32894967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
    Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD
    Trials; 2011 Jan; 12():3. PubMed ID: 21205325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
    Carey KM; Comee MR; Donovan JL; Kanaan AO
    Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
    Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
    Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
    Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
    BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.